Drug Discovery Today

JULY 8, 2021

The topic of this month’s newsletter from Drug Discovery Today is “Cardiovascular Drugs”.

Drugs 113

Drugs 113

Drug Patent Watch

JULY 9, 2021

This chart shows the pharmaceutical companies with the most patents in Poland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Poland? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Drugs 98

The Pharma Data

JULY 8, 2021

Biogen Inc. (Nasdaq:BIIB) today announced it will report second quarter 2021 financial results Thursday, July 22, 2021, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET. To access the live webcast, please go to the investors section of Biogen’s website at investors.biogen.com.

Biosimilars 52

Biosimilars Disease Therapies Treatment 52

Olympian Clinical Research

JULY 7, 2021

Social anxiety disorder, sometimes referred to as a social phobia, is a type of anxiety disorder characterized by extreme fear, distress, and anxiety in social settings. It’s important to note that being naturally more shy, reserved, or introverted is not the same thing as having social anxiety. While people with social anxiety may or may not exhibit shyness in social situations, it’s the uncontrollable fear, anxiety, and subsequent avoidance of social situations that differentiates someone with

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Drug Discovery Today

JULY 7, 2021

Cambridge Cognition spin-out targets schizophrenia and post-operative cognitive dysfunction

113

113

The Pharma Data

JULY 8, 2021

ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia. Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced the U.S. Food and Drug Administration (FDA) has approved an updated label for ADUHELM (aducanumab-avwa) injection 100 mg/mL solution. The update includes an addition to the Indications and Usage section of the label (Section 1) to emphasize the disease stages studied in the clinical trials, as seen

Clinical Trials 52

Clinical Trials FDA Approval Trials FDA 52

Crown Bioscience

JULY 5, 2021

Last month we hosted a webinar with Dr. Ludovic Bourré, Senior Director of Scientific Engagement at Crown Bioscience, focused on the next generation of preclinical models advancing bispecific T cell engager (BiTE) development.

52

52

Practical Cheminformatics

JULY 7, 2021

Another pointer to the FastPages site

40

40

Drug Patent Watch

JULY 7, 2021

Annual Drug Patent Expirations for XHANCE Xhance is a drug marketed by Optinose Us Inc and is included in one NDA. There are thirteen patents protecting this drug. XHANCE drug…. The post New patent for Optinose Us drug XHANCE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98

Drugs Marketing 98

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

The Pharma Data

JULY 8, 2021

People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of eight sites, including Salt Lake City. For those few vaccinated people who do still get an infection, or “breakthrough” cases, the study suggests that vaccines reduce the severity of COVID-19 symptoms and shorten its duration.

Vaccine 52

Vaccine Virus Nurses Hospitals 52

Drug Channels

JULY 7, 2021

ICYMI, Rite Aid recently released the financial results for its most recent fiscal quarter, which ended on May 29. Rite Aid’s pharmacy benefit manager (PBM) business, Elixir, continues to flail in an increasingly challenging market. I’ve long been skeptical of Rite Aid’s PBM strategy. As you will see below, last quarter’s results further validated my skepticism.

Pharmacy 40

Pharmacy Marketing Drugs 40

Pharmaceutical Development Group

JULY 7, 2021

Introduction FDA (can also be expanded as the Food and Drug Administration) is a bureau that administers the public’s welfare by controlling and surveillance of food products, medications, vaccines, medical devices, etc. There are certain rules and criteria for post marketing safety reporting of FDA combination products. What are combination products?

Production 52

Production FDA Packaging Vaccine 52

Drug Patent Watch

JULY 7, 2021

Annual Drug Patent Expirations for MYCAMINE Mycamine is a drug marketed by Astellas and is included in one NDA. It is available from one supplier. There is one patent protecting…. The post New patent expiration for Astellas drug MYCAMINE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98

Drugs Marketing 98

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

The Pharma Data

JULY 8, 2021

AbbVie (NYSE: ABBV) will announce its second-quarter 2021 financial results on Friday, July 30, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Production 52

Production Marketing 52

Drug Patent Watch

JULY 9, 2021

Annual Drug Patent Expirations for ALPHAGAN+P Alphagan P is a drug marketed by Allergan and is included in two NDAs. It is available from one supplier. There are eight patents…. The post New patent expiration for Allergan drug ALPHAGAN P appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

JULY 8, 2021

Annual Drug Patent Expirations for BRILINTA Brilinta is a drug marketed by Astrazeneca and is included in one NDA. It is available from two suppliers. There are four patents protecting…. The post New patent expiration for Astrazeneca drug BRILINTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

JULY 8, 2021

Annual Drug Patent Expirations for FASLODEX Faslodex is a drug marketed by Astrazeneca and is included in one NDA. It is available from one supplier. There are four patents protecting…. The post New patent expiration for Astrazeneca drug FASLODEX appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Drug Patent Watch

JULY 8, 2021

This chart shows the drugs with the most patents in Greece. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Greece? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Drug Patent Watch

JULY 8, 2021

Annual Drug Patent Expirations for XENLETA Xenleta is a drug marketed by Nabriva and is included in two NDAs. There are four patents protecting this drug. Drug patent litigation for…. The post New patent expiration for Nabriva drug XENLETA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

JULY 8, 2021

Annual Drug Patent Expirations for MYFEMBREE Myfembree is a drug marketed by Myovant Sciences and is included in one NDA. The generic ingredient in MYFEMBREE is estradiol; norethindrone acetate; relugolix.…. The post New patent for Myovant Sciences drug MYFEMBREE appeared first on DrugPatentWatch - Make Better Decisions.

Science 52

Science Drugs Marketing 52

Drug Patent Watch

JULY 8, 2021

Annual Drug Patent Expirations for EVEKEO+ODT Evekeo Odt is a drug marketed by Arbor Pharms Llc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Arbor Pharms drug EVEKEO ODT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Drug Patent Watch

JULY 7, 2021

This chart shows the pharmaceutical companies with the most insert dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most insert dosed drugs…. The post Which pharmaceutical companies have the most insert dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs 52

Drug Patent Watch

JULY 6, 2021

This chart shows the drugs with the most patents in Eurasian Patent Organization. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical drugs have the most drug patents in Eurasian Patent Organization? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Drug Patent Watch

JULY 6, 2021

Annual Drug Patent Expirations for LEVULAN Levulan is a drug marketed by Dusa and is included in one NDA. It is available from one supplier. There is one patent protecting…. The post New patent for DUSA drug LEVULAN appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

JULY 6, 2021

Annual Drug Patent Expirations for SUTAB+%28COPACKAGED%29 Sutab (copackaged) is a drug marketed by Braintree Labs and is included in one NDA. It is available from one supplier. There is one…. The post New patent for Braintree Labs drug SUTAB (COPACKAGED) appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

JULY 6, 2021

Annual Drug Patent Expirations for MYRBETRIQ+GRANULES Myrbetriq Granules is a drug marketed by Apgdi and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent for APGDI drug MYRBETRIQ GRANULES appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Pharma Data

JULY 6, 2021

GlaxoSmithKline plc (LSE/NYSE: GSK) and Alector (Nasdaq: ALEC), today announced a strategic global collaboration for the development and commercialisation of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels. PGRN is a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, making it one of the most attractive genetically validated targets for the development of new

Disease 52

Disease Science Treatment Clinical Development 52

The Pharma Data

JULY 6, 2021

Gaurav Gaiha, MD, DPhil, a member of the Ragon Institute of MGH, MIT and Harvard, studies HIV, one of the fastest-mutating viruses known to humankind. But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, piece

Vaccine 52

Vaccine Virus Research Immune Response 52

The Pharma Data

JULY 6, 2021

Sanofi highlights scientific innovations in the field of rare blood disorders at I STH 2021. New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. Clinical data and new research from Sanofi’s rare blood disorders portfolio of marketed and investigational therapies for people with hemophilia, immune thrombocytopenia (ITP) and acquired thrombotic thrombocytopenic purpura (aT

Therapies 52

Therapies Pharmacokinetics Treatment RNA 52